Clinical question
In patients with BPH (population), how effective are minimally invasive treatments (interventions), when compared with TURP (comparator), in improving symptom scores after surgery (outcome)?
Finding the best evidence
You decide to look for a well-designed systematic review on this topic using figure (Figure 1 ).
Evaluating the methods
Criteria for assessing validity of review articles have been previously described. 3 You decide to use the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist, 4 and are satisfied that the methods of the systematic review were strong. Turning to the results, you now assess whether the results are similar (consistent) from study to study; in other words, whether there is any heterogeneity among studies included in the systematic review.
What is heterogeneity?
In interpreting the results of a meta-analysis, it is important to consider not just the summary result but the degree to which the individual studies assess the same clinical question and that their results agree. Where the included patients and application of the interventions broadly similar? Are the results consistent (homogeneous) or do they vary so much that the summary is not reliable? Variability in the study results beyond that which could be expected by chance is called (statistical) heterogeneity. To some extent, it is inevitable that the estimated effects of a specific intervention will vary from study to study since two studies are never identical in design and conduct. 5 However, assessment of heterogeneity is not purely a statistical issue but also involves clinical judgement as to whether it is sensible to combine individual studies or not. Such considerations should occur prior to conducting a meta-analysis.
The first step for identifying heterogeneity is to visually inspect the forest plot. Is the direction and magnitude of effect consistent across studies? Do the confidence intervals for individual trials tend to overlap? A large difference in the point estimates with a lack of overlap in confidence intervals would indicate the presence of heterogeneity. that quantifies the inconsistency of study estimates. 5, 6 The I 2 ranges from 0% to 100% with larger values indicating a greater proportion of variability is attributable to heterogeneity. As a rough guideline, I 2 values higher than 50% may indicate a moderate to severe heterogeneity that requires caution. 6 Such statistical approaches are no panacea; they are influenced by the number and size of studies included in the meta-analysis and the underlying level of heterogeneity. 5, 7 The magnitude of heterogeneity (τ 2 value) could also be considered. When heterogeneity should be considered problematic is debatable.
In our example for the outcome of reduction in symptom scores after surgery, of the four trials comparing laser coagulation with TURP, three trials have point estimates (mean difference) greater than 0 (suggesting TURP is better than laser coagulation), whereas the other has point estimates less than 0 (suggesting laser coagulation is better; see Figure 1 ). Looking at the confidence intervals for the same comparison, the intervals are quite diffuse. The p-value for the χ 2 test is less than 0.10 signifying statistical evidence of heterogeneity. The corresponding I 2 is over 80% suggesting a high level of heterogeneity. Caution is therefore required in interpreting such results.
Similarly for the comparison of TUMT with TURP, the confidence interval of one of the studies (de la Rosette) does not overlap with the other two; Again, this is reflected in a high I 2 value of 84%.
Causes of heterogeneity
We distinguish the potential sources of heterogeneity (clinical and methodological differences) from observing (statistical) heterogeneity in the results. Variation in the estimated intervention effects may reflect differences in patient characteristics, the study setting, or how the interventions were implemented in the included studies In our example, the review authors postulate that differences in prostate size and symptom score at baseline may be important sources of heterogeneity observed when looking at the results after surgery. For laser coagulation, the authors also noted variation in operative technique and treatment protocols between trials (e.g. power settings, temperature and site or duration of laser application). They noted that it was difficult to assess their possible impact on intervention effects, as many trials did not describe the technologies used in sufficient details, a problem regularly encountered when conducting systematic reviews.
What can we do when there is heterogeneity?
In the presence of large unexplained heterogeneity investigators may choose not to pool the study results and only report the results of the individual studies.
Investigators may decide to conduct a random effects meta-analysis as was done for our example. Use of a random-effects model does not remove heterogeneity but formally allows for a degree of variability between individual trial results (random effects) while still assuming overall coherence. When there is heterogeneity, the confidence intervals around the summary (overall) estimate in the random-effects analysis will be wider than the corresponding one from a fixed-effect analysis. Many therefore see the random-effects approach as the more conservative (and arguably the default) option. 8 However, compared to a fixed-effect meta-analysis, smaller studies will be given more influence in a random-effects meta-analysis. Particular care is required when trial size varies greatly or there are few studies. This difference can be seen in Figure 2 where the random effects analysis of the same studies is conducted and the point estimate and the confidence interval for the summary estimate differ.
Applying the results to the care of your patient
Having applied the outlined methodology to assess the impact of heterogeneity in the case study, you take a cautious approach. Current evidence does not support Given this, you explain to your patient that the evidence suggests TURP to be at least as good as minimally invasive treatments and possibly the superior treatment of LUTS secondary to BPH in terms of symptom control at 12 months. You would also want to apply the same approach to the other important outcomes reported such as peak urine flow, the need for reoperation and possible adverse effects.
Conclusion
Urologists are often faced with systematic reviews of individual clinical trials with inconsistent results. In this case, it is important to assess the extent and magnitude of heterogeneity and ask whether investigators have sufficiently explored clinical and methodological sources of heterogeneity, which was the focus of a previous BJUI article. 9 Uncritical interpretation of meta-analysis can be misleading and misguide clinical practice. The ability to recognize and interpret heterogeneity is therefore critical to evidence-based practice of urology.
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